Strs Ohio lifted its holdings in G1 Therapeutics Inc (NASDAQ:GTHX) by 78.3% during the 2nd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 4,100 shares of the company’s stock after acquiring an additional 1,800 shares during the quarter. Strs Ohio’s holdings in G1 Therapeutics were worth $178,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds have also made changes to their positions in the company. BNP Paribas Arbitrage SA boosted its holdings in shares of G1 Therapeutics by 58.4% in the 1st quarter. BNP Paribas Arbitrage SA now owns 2,835 shares of the company’s stock worth $105,000 after acquiring an additional 1,045 shares in the last quarter. Ladenburg Thalmann Financial Services Inc. boosted its holdings in shares of G1 Therapeutics by 44.4% in the 1st quarter. Ladenburg Thalmann Financial Services Inc. now owns 3,900 shares of the company’s stock worth $144,000 after acquiring an additional 1,200 shares in the last quarter. Cubist Systematic Strategies LLC boosted its holdings in shares of G1 Therapeutics by 484.5% in the 1st quarter. Cubist Systematic Strategies LLC now owns 2,794 shares of the company’s stock worth $104,000 after acquiring an additional 2,316 shares in the last quarter. American International Group Inc. boosted its holdings in shares of G1 Therapeutics by 63.1% in the 1st quarter. American International Group Inc. now owns 8,637 shares of the company’s stock worth $320,000 after acquiring an additional 3,341 shares in the last quarter. Finally, New York State Common Retirement Fund boosted its holdings in shares of G1 Therapeutics by 53.5% in the 1st quarter. New York State Common Retirement Fund now owns 10,900 shares of the company’s stock worth $404,000 after acquiring an additional 3,800 shares in the last quarter. 69.18% of the stock is currently owned by institutional investors and hedge funds.

GTHX stock opened at $67.85 on Friday. G1 Therapeutics Inc has a fifty-two week low of $18.03 and a fifty-two week high of $69.57.

G1 Therapeutics (NASDAQ:GTHX) last posted its quarterly earnings data on Wednesday, August 8th. The company reported ($0.64) earnings per share for the quarter, topping the consensus estimate of ($0.65) by $0.01. sell-side analysts expect that G1 Therapeutics Inc will post -2.7 EPS for the current fiscal year.

In related news, Director Seth Rudnick sold 10,000 shares of the business’s stock in a transaction that occurred on Monday, August 6th. The shares were sold at an average price of $50.69, for a total value of $506,900.00. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, VP Jennifer K. Moses sold 750 shares of the business’s stock in a transaction that occurred on Thursday, July 5th. The stock was sold at an average price of $45.66, for a total transaction of $34,245.00. The disclosure for this sale can be found here. Insiders sold a total of 49,288 shares of company stock valued at $2,698,269 in the last 90 days. 15.92% of the stock is currently owned by corporate insiders.

GTHX has been the topic of several recent analyst reports. HC Wainwright initiated coverage on G1 Therapeutics in a report on Tuesday, May 29th. They issued a “buy” rating and a $61.00 target price on the stock. BidaskClub downgraded G1 Therapeutics from a “strong-buy” rating to a “buy” rating in a report on Thursday, May 31st. ValuEngine raised G1 Therapeutics from a “hold” rating to a “buy” rating in a report on Saturday, June 2nd. Zacks Investment Research downgraded G1 Therapeutics from a “hold” rating to a “sell” rating in a report on Wednesday, July 11th. Finally, Cowen reissued a “buy” rating on shares of G1 Therapeutics in a report on Thursday, August 9th. One investment analyst has rated the stock with a hold rating, six have issued a buy rating and one has assigned a strong buy rating to the company’s stock. The stock has an average rating of “Buy” and an average price target of $66.00.

About G1 Therapeutics

G1 Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of novel small molecule therapeutics for the treatment of patients with cancer in the United States. It is developing trilaciclib, an intravenous cyclin-dependent kinases (CDK) 4/6 inhibitor that is in Phase 1b/2a clinical trials for patients with small cell lung cancer, as well as Phase 2 clinical trial for patients with first-/second-/third-line metastatic triple-negative breast cancer; G1T38, an oral CDK4/6 inhibitor that is Phase 1b/2a clinical trials for the treatment of breast cancer; and G1T48, an oral selective estrogen receptor degrader, which is in preclinical development.

Recommended Story: Leveraged Buyout (LBO)

Want to see what other hedge funds are holding GTHX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for G1 Therapeutics Inc (NASDAQ:GTHX).

Institutional Ownership by Quarter for G1 Therapeutics (NASDAQ:GTHX)

Receive News & Ratings for G1 Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for G1 Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.